Tara L Lancaster

List of Publications by Year
in descending order

9	343	1478505 6	1588992 8
papers	citations	h-index	g-index

12	12	12	440
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. The Lancet Healthy Longevity, 2022, 3, e13-e21.	4.6	85
2	Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 2022, 23, 40-49.	14.5	145
3	Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI). Journal of Infectious Diseases, 2022, 226, 1877-1881.	4.0	5
4	COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell, 2022, 40, 584-586.	16.8	19
5	Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study. The Lancet Healthy Longevity, 2022, 3, e461-e469.	4.6	17
6	Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. The Lancet Healthy Longevity, 2021, 2, e544-e553.	4.6	43
7	The Role of the C-Terminal Lysine of S100P in S100P-Induced Cell Migration and Metastasis. Biomolecules, 2021, 11, 1471.	4.0	2
8	S100P enhances the motility and invasion of human trophoblast cell lines. Scientific Reports, 2018, 8, 11488.	3.3	18
9	Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naÃ¯ve residents of long-term care facilities who survive natural infection. Nature Aging, 0, , .	11.6	4